Randomized «FARVATER» study. Atorvastatin (10 and 20 mg/d) in treating patients with coronary heart disease and dyslipidemia: effects on lipids, C-reactive protein and fibrinogen levels

QR Code

Randomized «FARVATER» study. Atorvastatin (10 and 20 mg/d) in treating patients with coronary heart disease and dyslipidemia: effects on lipids, C-reactive protein and fibrinogen levels

Aim. To compare effects of atorvastatin in the doses of 10 and 20 mg/d on lipid profile, C-reactive protein (hsCRP), fibrinogen levels, as well as vascular wall structure and function in patients with coronary heart disease (CHD) and primary hyperlipidemia (PHL). Material and methods. Fifty CHD and...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. V. Susekov, M. Yu. Zubareva, M. I. Tripoten’, T. A. Rozhkova, O. A. Pogorelova, T. V. Balakhonova, V. P. Masenko, V. V. Kukharchuk
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2006-12-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	atorvastatin low-density lipoprotein cholesterol c-reactive protein endothelial dysfunction dyslipidemia coronary heart disease
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1403
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Randomized study FARVATER: Part II. Atorvastatin effects on endothelial function, vascular wall distensibility and stiffness
by: A. V. Susekov, et al.
Published: (2007-06-01)

Atorvastatin effectiveness in dyslipidemia correction among coronary heart disease and arterial hypertension patients with high risk of cardiovascular complications
by: E. V. Minakov, et al.
Published: (2007-10-01)

Dyslipidemia in the Russian Federation: population data, associations with risk factors
by: O. M. Drapkina, et al.
Published: (2023-12-01)

Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension
by: N. B. Amirov, et al.
Published: (1970-01-01)

SPECIFICS OF LIPID METABOLISM AND ATORVASTATIN EFFICACY IN TYPE 2 DIABETES WITH CARRIAGE OF VARIOUS POLYMORPHISMS OF CHOLESTEROL ETHER CARRYING PROTEIN TaqIB GENE
by: M. V. Kim, et al.
Published: (2015-10-01)

RATIONAL APPROACHES TO THE TREATMENT OF DYSLIPIDEMIA WITH DIFFERENT TOTAL CARDIOVASCULAR RISK AND ACUTE CORONARY SYNDROME
by: N. V. Perova, et al.
Published: (2015-09-01)

Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
by: M. V. Ezhov, et al.
Published: (2025-06-01)

Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study)
by: R. G. Oganov, et al.
Published: (2012-08-01)

Long-term low-dose atorvastatin therapy and prevention of macroangiopathy complications in elderly patients with Type 2 diabetes mellitus
by: G. A. Batrak, et al.
Published: (2010-06-01)

Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01)

USING A COMBINATION OF PERINDOPRIL, INDAPAMIDE AND ROSUVASTATIN IN THE TREATMENT OF PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA
by: O. M. Drapkina, et al.
Published: (2017-09-01)

CORRECTION OF DYSLIPIDEMIA: HISTORICAL ASPECT AND CURRENT VIEW OF THE PROBLEM (REVIEW, PART IІ)
by: Dmytro D. Diachuk, et al.
Published: (2025-04-01)

METABOLIC SYSTEM OF CHOLESTEROL ELIMINATION FROM TISSUES. POSSIBILITY OF ACTIVATION ITS KEY PARTS
by: N. V. Perova, et al.
Published: (2016-01-01)

About atypical dyslipidemia variants in myocardial infarction and unstable angina
by: B. M. Lipovetsky
Published: (2009-10-01)

EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, RUSSIA) GUIDELINES FOR THE DIAGNOSIS AND CORRECTION OF DYSLIPIDEMIA FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS (2020)
by: V. V. Kukharchuk, et al.
Published: (2020-06-01)

Double cholesterol inhibition — a new approach to effective control of hyperlipidemia and atherosclerosis
by: A. V. Susekov, et al.
Published: (2009-12-01)

Atorvastatin: evidence base 15 years later
by: A. V. Susekov, et al.
Published: (2011-06-01)

Combined lipid lowering therapy, including ezetimibe, in the post-infarction period
by: V. E. Oleynikov, et al.
Published: (2024-05-01)

Pleiotropic vasoprotective effects of high-dose atorvastatin therapy in the context of achieving the target low-density lipoprotein cholesterol in patients after myocardial infarction
by: L. I. Salyamova, et al.
Published: (2022-08-01)

Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
by: I. V. Sergienko, et al.
Published: (2023-12-01)

CENTRALISED SURVEY ON THE UNDERTREATMENT OF THE HYPERCHOLESTEROLEMIA IN RUSSIA (CEPHEUS)
by: S. A. Boytsov, et al.
Published: (2013-08-01)

ANALYSIS OF THE INTERACTION OF LIPID METABOLISM ALLELES IN DYSLIPIDEMIA
by: I. V. Nikolaev, et al.
Published: (2015-01-01)

THE EFFECTIVENESS OF OUTPATIENT AND HOSPITAL LIPID-LOWERING THERAPY IN PATIENTS WITH HIGH AND VERY HIGH CARDIOVASCULAR RISK DURING 2011-2015
by: S. A. Smetnev, et al.
Published: (2017-01-01)

Disorders of lipid metabolism. Clinical Guidelines 2023
by: M. V. Ezhov, et al.
Published: (2023-06-01)

Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome
by: Sh. A. Mostafa, et al.
Published: (2018-11-01)

Statin therapy and atherosclerosis regression
by: A. V. Susekov
Published: (1970-01-01)

Aggressive statin therapy in acute coronary syndrome: therapeutic potential of atorvastatin in the daily dose of 80 mg
by: A. N. Britov
Published: (2009-12-01)

Lipid-lowering therapy: modern possibilities and real clinical practice
by: A. V. Blokhina, et al.
Published: (2022-09-01)

EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION
by: R. D. Kurbanov, et al.
Published: (2015-09-01)

Associations of changes in lipid metabolism parameters and the severity of COVID-19 infection in Novosibirsk residents
by: A. A. Karaseva, et al.
Published: (2022-09-01)

Effect of phytocomposition on dyslipidemia in patients with SARS-CoV-2 infection at the health resort stage of treatment
by: I. A. Yatskov, et al.
Published: (2025-03-01)

Modern algorithms for statin therapy
by: V. A. Susekov
Published: (2023-11-01)

Lipid and pleiotropic effects of atorvastatin in patients with high cardiovascular risk
by: R. S. Karpov, et al.
Published: (2009-08-01)

Atorvastatin and simvastatin in clinical management of high-risk patients
by: S. A. Shalnova, et al.
Published: (2009-02-01)

Modulation of the intestinal microbiota as a means of primary and secondary prevention of cardiovascular catastrophes
by: V. A. Akhmedov
Published: (2023-11-01)

Analysis of the binary mixtures of amlodipine and atorvastatin by chemometric-spectophotometric method
by: Hayrettin Bulum, et al.
Published: (2025-06-01)

Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)
by: M. V. Kim, et al.
Published: (2015-03-01)

Linking Lipid Profile to Stress Urinary Incontinence in US Women: A National Cross-Sectional Study
by: Lu M, et al.
Published: (2025-06-01)

EFFICIENCY AND SAFETY ASSESSMENT OF GENERIC ATORVASTATINE IN PATIENTS WITH HYPERLIPIDEMIA
by: J. E. Semyonova, et al.
Published: (2015-12-01)

Nephroprotective effect of atorvastatin at a dose of 80 mg in patients with ST-segment elevation myocardial infarction with an invasive treatment strategy
by: A. D. Gavrilko, et al.
Published: (2023-11-01)